Last reviewed · How we verify
Licopid (glucosaminylmuramyl dipeptide)
Licopid (generic name: glucosaminylmuramyl dipeptide) is a glucosaminylmuramyl dipeptide drug. It is currently in unknown development.
Licopid works by interacting with a specific target in the body to produce a therapeutic effect.
Licopid is a small molecule. Its modality is classified as a small molecule according to ChEMBL.
At a glance
| Generic name | glucosaminylmuramyl dipeptide |
|---|---|
| Drug class | glucosaminylmuramyl dipeptide |
| Therapeutic area | Immunology |
| Phase | unknown |
Mechanism of action
Imagine your immune system as a security system that can sometimes get overactive and attack healthy cells. Licopid is thought to help calm down this system by interacting with a specific part of it, reducing inflammation and preventing damage to healthy tissues.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licopid CI brief — competitive landscape report
- Licopid updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Licopid
What is Licopid?
How does Licopid work?
What is the generic name of Licopid?
What drug class is Licopid in?
What development phase is Licopid in?
Related
- Drug class: All glucosaminylmuramyl dipeptide drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing